Bambusa Viscum Stannum Special Order
- Manufacturer
- Uriel Pharmacy Inc.
- Effective date
- 2014-09-29
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-01 02:06:06
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
INDICATIONS & USAGE SECTION
Directions: FOR TOPICAL USE ONLY.
DOSAGE & ADMINISTRATION SECTION
Apply to skin as needed. Under age 2: Consult a doctor.
OTC - ACTIVE INGREDIENT SECTION
Active Ingredients: Formica ex animale 5X, Bambusa e nodo 6X, Betonica ex herba 6X, Disci intervert. 6X, Rosmarinus ex herba 6X, Viscum Mali e pl. tota 6X, Stannum metallicum 7X, Jasper 12X, Equisetum ex herba 15X
INACTIVE INGREDIENT SECTION
Inactive Ingredients: Distilled water, Stearic acid, Isopropyl myristate, Lavender oil, Cetyl alcohol, Polyoxyl 40 stearate, Stearyl alcohol, Xanthan gum, Potassium sorbate, Frankincense oil, Myrrh oil, Grapefruit seed extract, Lactose
OTC - PURPOSE SECTION
Use: Temporary relief of headache.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF REACH OF CHILDREN.
WARNINGS SECTION
Warnings: FOR EXTERNAL USE ONLY. Do not use if allergic to any ingredient. Consult a doctor before use for serious conditions, if conditions worsen or persist, or accidental ingestion occurs. Contains traces of lactose. If pregnant or nursing, consult a doctor before use. Avoid contact with eyes. Do not use if safety seal is broken or missing.
OTC - QUESTIONS SECTION
Questions? Call 866.642.2858 Made with care by Uriel, East Troy, WI 53120
www.urielpharmacy.com
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 48951-2108-5 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-e938-f424-e053-dadaa90a57ce | Bambusa Viscum Stannum Special Order |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 48951-2108-5 | Bambusa Viscum Stannum Special Order | 60 g in 1 TUBE | CREAM | 60 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 48951-2108 | BAMBUSA VISCUM STANNUM SPECIAL ORDER CREAM [URIEL PHARMACY INC.] | 1 | Legacy NDC, 1 package rows | 20141031_690f9afc-f646-490d-b59f-5efbf507797e.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| BAMBUSA VULGARIS WHOLE | ACTIVE INGREDIENT | WCD45M1BSK | 1 | |
| BOS TAURUS INTERVERTEBRAL DISC | ACTIVE INGREDIENT | 0A04Z76C13 | 1 | |
| COLLOIDAL SILICON DIOXIDE | ACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| EQUISETUM ARVENSE TOP | ACTIVE INGREDIENT | 1DP6Y6B65Z | 1 | |
| FORMICA RUFA | ACTIVE INGREDIENT | 55H0W83JO5 | 1 | |
| ROSMARINUS OFFICINALIS FLOWERING TOP | ACTIVE INGREDIENT | 8JM482TI79 | 1 | |
| STACHYS OFFICINALIS | ACTIVE INGREDIENT | UO9989Y17N | 1 | |
| TIN | ACTIVE INGREDIENT | 387GMG9FH5 | 1 | |
| VISCUM ALBUM FRUITING TOP | ACTIVE INGREDIENT | BK9092J5MP | 1 | |
| BAMBUSA VULGARIS WHOLE | ACTIVE MOIETY | WCD45M1BSK | 1 | |
| BOS TAURUS INTERVERTEBRAL DISC | ACTIVE MOIETY | 0A04Z76C13 | 1 | |
| COLLOIDAL SILICON DIOXIDE | ACTIVE MOIETY | ETJ7Z6XBU4 | 1 | |
| EQUISETUM ARVENSE TOP | ACTIVE MOIETY | 1DP6Y6B65Z | 1 | |
| FORMICA RUFA | ACTIVE MOIETY | 55H0W83JO5 | 1 | |
| ROSMARINUS OFFICINALIS FLOWERING TOP | ACTIVE MOIETY | 8JM482TI79 | 1 | |
| STACHYS OFFICINALIS | ACTIVE MOIETY | UO9989Y17N | 1 | |
| TIN | ACTIVE MOIETY | 387GMG9FH5 | 1 | |
| VISCUM ALBUM FRUITING TOP | ACTIVE MOIETY | BK9092J5MP | 1 | |
| CETYL ALCOHOL | INACTIVE INGREDIENT | 936JST6JCN | 1 | |
| CITRUS PARADISI SEED | INACTIVE INGREDIENT | 12F08874Y7 | 1 | |
| FRANKINCENSE OIL | INACTIVE INGREDIENT | 67ZYA5T02K | 1 | |
| ISOPROPYL MYRISTATE | INACTIVE INGREDIENT | 0RE8K4LNJS | 1 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 1 | |
| LAVENDER OIL | INACTIVE INGREDIENT | ZBP1YXW0H8 | 1 | |
| MYRRH OIL | INACTIVE INGREDIENT | H74221J5J4 | 1 | |
| POLYOXYL 40 STEARATE | INACTIVE INGREDIENT | 13A4J4NH9I | 1 | |
| POTASSIUM SORBATE | INACTIVE INGREDIENT | 1VPU26JZZ4 | 1 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 1 | |
| STEARYL ALCOHOL | INACTIVE INGREDIENT | 2KR89I4H1Y | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 | |
| XANTHAN GUM | INACTIVE INGREDIENT | TTV12P4NEE | 1 |
Products#
Every source-derived product name is available through these pages.
- Bambusa Viscum Stannum Special Order
- FORMICA RUFA
- BAMBUSA VULGARIS WHOLE
- STACHYS OFFICINALIS
- BOS TAURUS INTERVERTEBRAL DISC
- ROSMARINUS OFFICINALIS FLOWERING TOP
- VISCUM ALBUM FRUITING TOP
- TIN
- COLLOIDAL SILICON DIOXIDE
- EQUISETUM ARVENSE TOP
- WATER
- STEARIC ACID
- ISOPROPYL MYRISTATE
- LAVENDER OIL
- CETYL ALCOHOL
- POLYOXYL 40 STEARATE
- STEARYL ALCOHOL
- XANTHAN GUM
- POTASSIUM SORBATE
- FRANKINCENSE OIL
- MYRRH OIL
- CITRUS PARADISI SEED
- LACTOSE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 48951-2108 | 48951-2108-5 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | SUSPENSION/ DROPS / ORAL | 22 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | AEROSOL / TOPICAL | 9.3 %w/w | ||
| POLYOXYL 40 STEARATE | POLYOXYL 40 STEARATE TYPE I | 13A4J4NH9I | GRANULE / ORAL | NA | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | EMULSION / OPHTHALMIC | 0.47 %w/v | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | AEROSOL, FOAM / TOPICAL | 0.27 %w/w | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | AEROSOL, FOAM / VAGINAL | 4 %w/w | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SOLUTION / ORAL | 1000 mg/15ml | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | CREAM / VAGINAL | 1088 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | TABLET, ORALLY DISINTEGRATING / ORAL | 9 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TABLET, EXTENDED RELEASE / ORAL | 528 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | GEL / TOPICAL | 29 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | TABLET, EXTENDED RELEASE / ORAL | 132 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| POLYOXYL 40 STEARATE | POLYOXYL 40 STEARATE TYPE I | 13A4J4NH9I | LOTION / TOPICAL | 3 %w/w | ||
| STEARYL ALCOHOL | STEARYL ALCOHOL | 2KR89I4H1Y | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 120 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SOLUTION/ DROPS / OPHTHALMIC | 0.47 %w/v | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | LOZENGE / ORAL | 1264 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | GRANULE, FOR SUSPENSION / ORAL | 450 mg | ||
| POLYOXYL 40 STEARATE | POLYOXYL 40 STEARATE TYPE I | 13A4J4NH9I | TABLET, FILM COATED / ORAL | 2 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 59 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | CAPSULE / ORAL | NA | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | OIL / AURICULAR (OTIC) | 36 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| STEARYL ALCOHOL | STEARYL ALCOHOL | 2KR89I4H1Y | AEROSOL, FOAM / TOPICAL | 37 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TABLET, FILM COATED / ORAL | 0.08 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | PASTE / ORAL | 1050 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | LOTION / TOPICAL | 0.3 %w/v | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | SUSPENSION / RECTAL | 452 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| POLYOXYL 40 STEARATE | POLYOXYL 40 STEARATE TYPE I | 13A4J4NH9I | CREAM / TOPICAL | 86000 mg | ||
| POLYOXYL 40 STEARATE | POLYOXYL 40 STEARATE TYPE I | 13A4J4NH9I | SUSPENSION / AURICULAR (OTIC) | 1 %w/v | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | CREAM / VAGINAL | 50 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | OINTMENT / TOPICAL | 7 %w/w | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | SOLUTION / TOPICAL | NA | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | AEROSOL, FOAM / TOPICAL | 144 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | GEL, METERED / TRANSDERMAL | 50 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | SOLUTION / ORAL | 84 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | TABLET / ORAL | NA | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | FILM / TRANSDERMAL | 58.08 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SUSPENSION / ORAL | 400 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | POWDER, FOR SUSPENSION / ORAL | 600 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | GRANULE, FOR SUSPENSION / ORAL | 80 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, DELAYED RELEASE / ORAL | 80 mg | ||
| STEARYL ALCOHOL | STEARYL ALCOHOL | 2KR89I4H1Y | CREAM / TOPICAL | 162000 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | FILM, EXTENDED RELEASE / TRANSDERMAL | 20.4 mg | ||
| POLYOXYL 40 STEARATE | POLYOXYL 40 STEARATE TYPE I | 13A4J4NH9I | SOLUTION / OPHTHALMIC | 7 %w/w | ||
| POLYOXYL 40 STEARATE | POLYOXYL 40 STEARATE TYPE I | 13A4J4NH9I | OINTMENT / OPHTHALMIC | NA | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | CREAM / TOPICAL | 0.25 %w/w | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | EMULSION / TOPICAL | NA | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | PASTE / ORAL | 48 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, COATED / ORAL | NA | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, CHEWABLE / ORAL | 180 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| a0e22454-5ba9-47f1-8003-8ffd8e9ae0ef | 690f9afc-f646-490d-b59f-5efbf507797e | 2014-09-29 | Warnings | a0e22454-5ba9-47f1-8003-8ffd8e9ae0ef 690f9afc-f646-490d-b59f-5efbf507797e |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
